Remedio | Mamacrowd

TAX Bonus

Innov SME



Sempli Farma


Sempli Farma® revolutionizes the way drugs are taken through a repackaging service in Custom Unit Doses in pharmacies.

  • Revenues €1.23 mln in 2022 (+965% vs 2021) and positive EBITDA of 13.1%

  • More than 2,500 patients service users through 61 partner pharmacies and 26 RSAs

  • More than 50 percent of pharmacies providing the automated service in Italy are Sempli Farma® branded

  • High potential for market growth: 8.8 mln Italians taking more than 5 tablets a day

Professional Investor

Professional Inv.

Goal min 150 k€

Goal max 588,57 k€

Total Collected

324.631 €




7,5 Mln€

Minimum goal

150 k€

Minimum Order

498,52 €

Days left


  • Project
  • Market and Target
  • Business Model
  • Financial projections
  • Use of funds
  • Rewards for Investors
  • Team
immagine copertina


Sempli Farma®, a brand of Remedio Srl, proposes that pharmacies become repackaging centers for sachets ("Personalized Unit Doses") of oral solid drug therapies.

The sachets make it easier and safer for patients to take the right drug, with the right dose, at the right time, thus increasing adherence to therapies, the lack of which touches 50 percent of the 8.8 million poly-treated people in Italy (those who take more than 5 tablets a day), causing morbidity and avoidable costs for the SSN of about 19 billion a year (emergency room accesses, hospitalizations, treatments).

By investing you will become a partner in one of the first movers of a booming market. Sempli Farma®'s service already has 18 repackaging center pharmacies and 43 satellite pharmacies, with more than 2,500 patients served. Revenues for 2022 were € 1.23 mln, with EBITDA 13.1%.

The company's strategic design touches on three points:

  1. Build a network of community pharmacies, spread throughout the territory, focused on therapeutic adherence;
  2. Carry out an observational study to demonstrate the benefits in terms of therapeutic adherence and thus quality of patient health and reduction of avoidable health care costs, so as to help make the service reimbursed by the SSN;
  3. Create a therapeutic adherence marketplace, to sell the service online, including B2C (for this purpose we have already obtained 650k funding, including 180k in grants, from Invitalia).

Specifically, Sempli Farma® provides pharmacies with a sophisticated hardware & software system, which repackages into sachets the medications (tablets or tablets) that the individual patient needs to take at a certain time of the day. The sachets are dispensed either with a simple dispenser, in which the string of sachets (roll) is ordered chronologically, or with a "smart dispenser, " which dispenses the right sachet, already cut, at the predetermined time and reminds the patient, with beeps and lights, that it is time to take it.

Sempli Farma® brings technological, organizational, marketing & sales know-how to pharmacies. It sells repackaging technologies, access to the platform that communicates with prescription and medication management systems (recurrent fees from maintenance, support, consumables and software use licenses). It also receives patient/day fees for Site Management service (which maximizes in-house labor productivity to reduce unit production costs) and Business Development service (marketing activities and patient research for the pharmacy). Other recurrent revenues come from the development of the therapeutic adherence marketplace (platform access and online sales of the Sempli Farma® repackaging service and other related goods and services).

Tax benefits of 30% apply on Sempli Farma.

Sempli Farma reserves the right of "liquidation preference" for all investors participating in the campaign, who will therefore be reimbursed first in the event of an exit than the company's other shareholders (according to the order of preference indicated in the bylaws). All conditions are published in the bylaws found in the Documents section.

On the campaign is available the optional Rubrication free of charge for the Investor as the costs are borne by Sempli Farma.


Want to find out more about this project?

Do you already have an account?

Sempli Farma

The information on the offer is not subject to approval by Consob. The Offering company is solely responsible for the completeness and truthfulness of the data and information provided by the latter. The investor's attention is also drawn to the fact that the investment, even indirect, through OICR or companies that invest mainly in financial instruments issued by innovative startups and SMEs is illiquid and characterised by a very high risk.

By using the services of Mamacrowd you accept our cookies policy. We and our partners operate globally and use cookies, including for statistical, advertising and customisation purposes.

Show preferences